FibroGen, Inc (FGEN) Shares Bought by Principal Financial Group Inc.
Principal Financial Group Inc. lifted its position in FibroGen, Inc (NASDAQ:FGEN) by 2.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 139,465 shares of the biopharmaceutical company’s stock after acquiring an additional 3,420 shares during the quarter. Principal Financial Group Inc. owned 0.20% of FibroGen worth $4,504,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Ameritas Investment Partners Inc. acquired a new position in shares of FibroGen in the 1st quarter worth approximately $111,000. SG Americas Securities LLC increased its holdings in shares of FibroGen by 6.5% in the 2nd quarter. SG Americas Securities LLC now owns 6,747 shares of the biopharmaceutical company’s stock valued at $218,000 after acquiring an additional 412 shares during the last quarter. BNP Paribas Arbitrage SA raised its position in shares of FibroGen by 589.1% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 7,401 shares of the biopharmaceutical company’s stock valued at $239,000 after acquiring an additional 6,327 shares in the last quarter. Parametric Portfolio Associates LLC acquired a new stake in shares of FibroGen during the 1st quarter valued at approximately $249,000. Finally, Great West Life Assurance Co. Can raised its position in shares of FibroGen by 107.0% during the 2nd quarter. Great West Life Assurance Co. Can now owns 8,694 shares of the biopharmaceutical company’s stock valued at $280,000 after acquiring an additional 4,494 shares in the last quarter. Institutional investors own 47.49% of the company’s stock.
Several equities analysts recently issued reports on the company. Jefferies Group LLC restated a “buy” rating and set a $75.00 price objective on shares of FibroGen in a research note on Tuesday, September 12th. Goldman Sachs Group, Inc. (The) downgraded shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price objective for the company. in a report on Friday, July 21st. BidaskClub lowered shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Stifel Nicolaus reiterated a “buy” rating and set a $80.00 target price on shares of FibroGen in a research note on Thursday, September 14th. Finally, Citigroup Inc. reiterated a “buy” rating and set a $48.00 target price on shares of FibroGen in a research note on Monday, June 26th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $60.17.
FibroGen, Inc (NASDAQ:FGEN) opened at 56.05 on Wednesday. The stock’s 50 day moving average price is $48.38 and its 200 day moving average price is $34.57. The company’s market capitalization is $3.99 billion. FibroGen, Inc has a 12-month low of $15.60 and a 12-month high of $56.15.
FibroGen (NASDAQ:FGEN) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.47) by ($0.01). FibroGen had a negative net margin of 105.59% and a negative return on equity of 64.42%. The company had revenue of $29.00 million during the quarter, compared to analyst estimates of $34.80 million. On average, equities research analysts anticipate that FibroGen, Inc will post ($1.80) earnings per share for the current fiscal year.
In other FibroGen news, VP Pat Cotroneo sold 4,000 shares of the company’s stock in a transaction dated Thursday, July 6th. The shares were sold at an average price of $34.00, for a total transaction of $136,000.00. Following the sale, the vice president now directly owns 167,366 shares of the company’s stock, valued at $5,690,444. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Thomas B. Neff sold 18,900 shares of the company’s stock in a transaction dated Thursday, July 6th. The stock was sold at an average price of $33.53, for a total transaction of $633,717.00. Following the sale, the chief executive officer now directly owns 3,330,780 shares in the company, valued at $111,681,053.40. The disclosure for this sale can be found here. Insiders have sold 506,828 shares of company stock valued at $22,574,671 over the last quarter. Corporate insiders own 14.90% of the company’s stock.
FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.
Receive News & Stock Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related stocks with our FREE daily email newsletter.